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Abstract
Background: Accurately identifying women with dense breasts (Breast Imaging Reporting and Data System
[BI-RADS] heterogeneously or extremely dense) who are at high breast cancer risk will facilitate discussions of
supplemental imaging and primary prevention. We examined the independent contribution of dense breast
volume and BI-RADS breast density to predict invasive breast cancer and whether dense breast volume combined
with Breast Cancer Surveillance Consortium (BCSC) risk model factors (age, race/ethnicity, family history of breast
cancer, history of breast biopsy, and BI-RADS breast density) improves identifying women with dense breasts at
high breast cancer risk.
Methods: We conducted a case-control study of 1720 women with invasive cancer and 3686 control subjects. We
calculated ORs and 95% CIs for the effect of BI-RADS breast density and Volpara™ automated dense breast volume
on invasive cancer risk, adjusting for other BCSC risk model factors plus body mass index (BMI), and we compared
C-statistics between models. We calculated BCSC 5-year breast cancer risk, incorporating the adjusted ORs
associated with dense breast volume.
Results: Compared with women with BI-RADS scattered fibroglandular densities and second-quartile dense breast
volume, women with BI-RADS extremely dense breasts and third- or fourth-quartile dense breast volume (75% of
women with extremely dense breasts) had high breast cancer risk (OR 2.87, 95% CI 1.84–4.47, and OR 2.56, 95% CI
1.87–3.52, respectively), whereas women with extremely dense breasts and first- or second-quartile dense breast
volume were not at significantly increased breast cancer risk (OR 1.53, 95% CI 0.75–3.09, and OR 1.50, 95% CI 0.82–2.
73, respectively). Adding continuous dense breast volume to a model with BCSC risk model factors and BMI
increased discriminatory accuracy compared with a model with only BCSC risk model factors (C-statistic 0.639, 95%
CI 0.623–0.654, vs. C-statistic 0.614, 95% CI 0.598–0.630, respectively; P < 0.001). Women with dense breasts and
fourth-quartile dense breast volume had a BCSC 5-year risk of 2.5%, whereas women with dense breasts and first-
quartile dense breast volume had a 5-year risk ≤ 1.8%.
Conclusions: Risk models with automated dense breast volume combined with BI-RADS breast density may better
identify women with dense breasts at high breast cancer risk than risk models with either measure alone.
Keywords: Breast density, Breast cancer risk, Dense volume
* Correspondence: karla.kerlikowske@ucsf.edu
1Department of Epidemiology and Biostatistics, University of California, San
Francisco, CA, USA
2General Internal Medicine Section, San Francisco Veterans Affairs Medical
Center, 111A1, 4150 Clement Street, San Francisco, CA 94121, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kerlikowske et al. Breast Cancer Research  (2017) 19:97 
DOI 10.1186/s13058-017-0887-5
Background
Many studies using both qualitative and quantitative
breast density measures have found women with high
breast density (greater amount of breast and connective
tissue compared with fat) are at increased breast cancer
risk [1]. The Breast Imaging Reporting and Data System
(BI-RADS) breast density categories estimated subject-
ively by radiologists [2] is the standard for reporting
breast density in clinical practice in the United States.
Quantitative breast density measures are now available
with commercial (QuantraTM, Hologic, Inc., Marlbor-
ough, MA, USA; and VolparaTM, Volpara Solutions/
Matakina Technology, Wellington, New Zealand) and
publicly available (Laboratory for Individualized Breast
Radiodensity Assessment [LIBRA]) software that can be
used in clinical practice. Breast cancer associations
appear to be similar with qualitative and quantitative
measures examined [3–5].
BI-RADS breast density is estimated visually and re-
flects density quantity, distribution, and parenchymal
pattern, whereas quantitative measures algorithmically
assess absolute dense breast volume. The correlation of
clinical BI-RADS density with quantitative dense breast
volume (QuantraTM, VolparaTM) is modest [6–8]. Dis-
cordant associations between BI-RADS density and
dense breast volume have been reported for black and
Asian women. Asian women have a higher proportion of
dense breasts (BI-RADS heterogeneously or extremely
dense) than white women, but dense breast volume is
lower in Asian women [4]. Conversely, black and white
women have a similar proportion with dense breasts, but
dense breast volume is higher in black than in white
women [8]. This suggests clinical BI-RADS density and
quantitative density measures may be measuring different
aspects of breast density and possibly breast cancer risk.
About 50% of women with dense breasts are at low to
average breast cancer risk (5-year risk ≤ 1.67%) [9]. Ac-
curately identifying women with dense breasts who are
at high breast cancer risk (5-year risk ≥ 2.5%) will facili-
tate discussions of supplemental imaging and primary
prevention. Combining a qualitative or quantitative
breast density measure with clinical risk factors esti-
mates a woman’s breast cancer risk more accurately than
does either measure alone [3, 10–12]. No breast cancer
risk prediction models have combined clinical risk fac-
tors and qualitative and quantitative measures of breast
density. An advantage of incorporating dense breast vol-
ume into risk prediction models is that it is independent
of clinical risk factors and only weakly confounded by
body mass index (BMI) [4].
We evaluated the independent contribution and im-
proved discriminatory accuracy of adding dense breast
volume to the Breast Cancer Surveillance Consortium
(BCSC) risk prediction model [3], which includes age,
race/ethnicity, first-degree family history of breast can-
cer, history of breast biopsy, and BI-RADS breast density
with additional adjustment for BMI to identify women
with dense breasts who are at high breast cancer risk.
Methods
Study sample
Study participants were in one of three case-control
studies nested within large prospective breast imaging
cohorts. The San Francisco Mammography Registry
(SFMR) and Vermont Breast Cancer Surveillance System
(VBCSS) participate in the National Cancer Institute-
funded BCSC (http://www.bcsc-research.org/) [13]. Both
registries obtain annual institutional review board ap-
proval and passive permission for data collection and en-
rollment of participants, as well as data linkages for
research purposes, and both received a Federal Certifi-
cate of Confidentiality that protects the identities of re-
search participants. For the Mayo Clinic screening
cohort, a waiver of informed consent and Health Insur-
ance Portability and Accountability Act authorization
from the participants was approved by the institutional
review board. Only individuals who had not refused per-
mission to use their medical records for research (ac-
cording to Minnesota Research Authorization Statute)
were included from the Mayo Clinic cohort [14].
The SFMR obtained “for processing” digital screening ex-
aminations done with Selenia machines (Hologic Inc.) at
four facilities since 2006, and the VBCSS obtained them
from one facility for screenings done since 2007, which
serve as the underlying screening mammography cohort
for each registry. Incident invasive breast cancers reported
to the California Cancer Registry (n = 1052) or the Vermont
Cancer Registry and pathology databases (n = 288) from
January 2007 through November 2012 with a raw digital
screening examination at least 6 months prior to diagnosis
with no upper time limit were included. Two control sub-
jects (n = 2678) without prior breast cancer were matched
to each case on age within 5 years, race, date of screening
examination within 1 year, mammography machine, and fa-
cility. The Mayo Clinic cohort obtained “for processing”
digital images from Selenia machines from April 2008
through December 2013 from women in the tristate region
of Minnesota, Iowa, and Wisconsin. Incident invasive
breast cancers from this region reported to the Mayo Clinic
tumor registry through December 2013 (n = 380) were in-
cluded. Approximately three control subjects (n = 1008)
without prior breast cancer were matched to each case on
age within 5 years, race, state of residence, date of screening
examination within 1 year, and mammography machine.
We ensured that each control subject had at least one nor-
mal screening mammogram on or after the corresponding
case’s diagnosis date. Our total sample consisted of 1720 in-
vasive cases and 3686 control subjects.
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Measurement of risk factors
Information on age, first-degree family history of breast
cancer, race/ethnicity, prior breast biopsy history, height,
weight, and age at first live birth were obtained from
self-report (SFMR and VBCSS) at the time of mammog-
raphy and from self-report or medical record review
(height and weight) for the Mayo Clinic cohort. BMI
was calculated by dividing weight in kilograms by height
in square meters. Race/ethnicity was coded using the ex-
panded definition currently used in the Surveillance,
Epidemiology, and End Results program and U.S. vital
statistics (non-Hispanic White, non-Hispanic black,
Asian/Pacific Islander, Native American/Alaskan Native,
Hispanic, other/mixed race). Age at first live birth was
dichotomized as nulliparous or age ≥ 30 years for first
live birth compared with age at first birth < 30 years.
BI-RADS breast density and dense breast volume
Practicing radiologists classified breast density as part of
routine clinical practice at the time of mammography in-
terpretation using the BI-RADS® density categories [2]: a
= almost entirely fat, b = scattered fibroglandular densities,
c = heterogeneously dense, and d = extremely dense. Vol-
para™ version 1.5.0, which is the most common automated
3D density measurement tool used in clinical practice and
research settings, is a fully automated method for asses-
sing volumetric breast density that uses the measured
breast thickness and X-ray attenuations in the “for pro-
cessing” image to create estimates of dense and nondense
tissue volume for each pixel. Summing the dense pixel
volumes provides total dense breast volume. Volpara uses
proprietary algorithms to calculate breast thickness and
determine dense tissue volume [15] by averaging measures
of each breast. For this study, we used the dense breast
volume output from the vendor-specific software per
woman, incorporating all four views (craniocaudal and
mediolateral oblique of both breasts) of raw digital images
as done in the clinical setting.
Statistical methods
We compared frequency distributions of demographics
and risk factors between cases and control subjects.
Dense breast volume quartiles were defined using
control subjects from all sites. Within each BI-RADS
category, the proportion of cases and control subjects
within each dense breast volume quartile was calculated.
Spearman’s correlation coefficient was calculated to as-
sess the association of BI-RADS density categories with
continuous dense breast volume.
Conditional logistic regression stratified on matched
set was used to examine the effects of BI-RADS density
and dense breast volume on invasive breast cancer risk.
Associations were summarized with ORs and 95% CIs,
and with AUROC or C-statistics, which accounted for
the matched study design. Differences in C-statistics be-
tween models were tested using the SEs estimated from
5000 bootstrap samples. Models were adjusted for age,
race/ethnicity, first-degree family history of breast can-
cer, history of benign breast biopsy, and BMI (continu-
ous). We used the second BI-RADS category as a
reference to allow for estimations of risk at the lowest
and highest categories and because it is the most preva-
lent category. Study heterogeneity was evaluated by in-
cluding an interaction term between study site and
breast density measurement. Initially, we fit a model
evaluating the association among all possible combina-
tions of BI-RADS density and quartiles of dense breast
volume in reference to women with scattered fibrogland-
ular density and second-quartile dense breast volume.
Differences in breast cancer association among combina-
tions of BI-RADS density and quartiles of dense breast
volume were evaluated by including a multiplicative
interaction term. Then, separate models were evaluated
that included BCSC clinical risk factors, with and with-
out BMI, plus one or more measure(s) of breast density:
BI-RADS density, continuous dense breast volume, and
BI-RADS density plus continuous dense breast volume.
Continuous dense breast volume was log-transformed
and divided by its SD.
To examine the absolute risk associated with quartiles
of dense breast volume, we incorporated the adjusted ORs
associated with dense breast volume into the BCSC
model. ORs for each quartile from the fully adjusted
model were standardized for attributable fraction so that
they measured increased or decreased risk relative to aver-
age risk. We calculated the estimated 5-year absolute risk
from both the original model and the updated model for
each subject and summarized these absolute risks across
BI-RADS and dense breast volume categories. For those
with heterogeneously or extremely dense breasts, the pro-
portion of control subjects with risks ≥ 2.5% were calcu-
lated for each model. These proportions were then used
to calculate the net gain in reclassification for the updated
risk model including dense breast volume.
Analyses were performed using SAS version 9.4 soft-
ware (SAS Institute, Cary, NC, USA). Two-sided statis-
tical tests were used, and P values < 0.05 were
considered to be statistically significant.
Results
We compared 1720 women with invasive breast cancer
with 3686 matched women without breast cancer with
breast density measured, on average, 2.4 years (range
6 months to 6 years) before cancer diagnosis. Women
with invasive cancer were more likely to be nulliparous
or ≥ 30 years of age at first live birth, to have a family
history of breast cancer, to have heterogeneously or ex-
tremely dense breasts, and to have higher mean dense
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breast volume (Table 1). A wide distribution of dense
breast volume was observed within each BI-RADS dens-
ity category (Table 2). Surprisingly, about one-third
(30.5%) of control subjects with almost entirely fat
breasts had first-quartile dense breast volume
(≤35.9 ml), and about half (54.1%) with extremely dense
breasts had fourth-quartile (>70.0 ml) dense breast vol-
ume. The correlation coefficient between continuous
dense breast volume and BI-RADS density was r = 0.38
(95% CI 0.34–0.42) for cases and r = 0.31 (95% CI 0.29–
0.34) for control subjects.
Quartiles of dense breast volume and BI-RADS density as-
sociations with breast cancer risk
In multivariable models that included clinical risk factors in
the BCSC risk model with additional adjustment for BMI,
compared with women with BI-RADS scattered fibrogland-
ular density and second-quartile dense breast volume,
women with BI-RADS extremely dense breasts and third
or fourth-quartile dense breast volume (75% of women with
extremely dense breasts) had high breast cancer risk (OR
2.87, 95% CI 1.84–4.47, and OR 2.56, 95% CI 1.87–3.52, re-
spectively), whereas women with extremely dense breasts
and first- or second-quartile dense breast volume were not
at significantly increased breast cancer risk (OR 1.53, 95%
CI 0.75–3.09, and OR 1.50, 95% CI 0.82–2.73, respectively)
(Table 3). Women with BI-RADS almost entirely fat breasts
and first- or second-quartile dense breast volume (63% of
women with fatty breasts) had the lowest breast cancer risk
(OR 0.63, 95% CI 0.45–0.89, and OR 0.60, 95% CI 0.43–
0.84, respectively). There was no significant interaction be-
tween BI-RADS density and dense breast volume associa-
tions with breast cancer (P = 0.75).
Continuous dense breast volume and BI-RADS density
and breast cancer risk associations
In multivariable models that included risk factors in the
BCSC risk model with additional adjustment for BMI,
Table 1 Characteristics of study sample
Invasive breast cancer cases (n = 1720) Matched control subjects (n = 3686)
Age, years, mean (SD) 59.5 (12.1) 59.6 (12.0)
Body mass index, kg/m2, mean (SD) 26.3 (5.7) 26.2 (5.7)
Dense breast volume,a ml, median (IQR) 57.8 (41.0–82.5) 50.7 (36.8–70.2)
Age at first live birth, n (%)
< 30 years 856 (50.1%) 2085 (56.6%)
None or ≥ 30 years 852 (49.9%) 1600 (43.4%)
Family history of breast cancer,b n (%)
No 1218 (71.2%) 2991 (81.2%)
Yes 493 (28.8%) 693 (18.8%)
History of breast biopsy, n (%)
No 1304 (76.4%) 3040 (82.6%)
Yes 402 (23.6%) 641 (17.4%)
Race/ethnicity, n (%)
White 1380 (80.3%) 3012 (81.7%)
Asian 218 (12.7%) 437 (11.9%)
Black 34 (2.0%) 67 (1.8%)
Hispanic 37 (2.2%) 101 (2.7%)
Other 50 (2.9%) 69 (1.9%)
BI-RADS breast density,c n (%)
Almost entirely fat (a) 233 (13.5%) 731 (19.8%)
Scattered fibroglandular densities (b) 668 (38.8%) 1557 (42.2%)
Heterogeneously dense (c) 600 (34.9%) 1115 (30.2%)
Extremely dense (d) 219 (12.7%) 283 (7.7%)
BI-RADS Breast Imaging Reporting and Data System
Data are presented as number (percent) missing for cases and control subjects for age at first birth (13 [0.2%]), family history of breast cancer (11 [0.2%]), history
of breast biopsy (19 [0.4%]), and race/ethnicity (3 [0.1%])
aMeasured with Volpara software
bMother, sister, or daughter with breast cancer
cBI-RADS breast density: a = almost entirely fat, b = scattered fibroglandular densities, c = heterogeneously dense, d = extremely dense
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women with BI-RADS extremely dense breasts were at
2.45 times higher risk than women with scattered fibro-
glandular densities (Table 4). In a separate model, con-
tinuous dense breast volume increased risk 33% per 1-
SD increase in dense breast volume. When combining
continuous dense breast volume and BI-RADS density
in the same multivariable model, associations with breast
cancer were attenuated, but both density variables
remained statistically significant (Table 4). There was no
evidence of study heterogeneity for models with BI-
RADS density or dense breast volume assessed by quar-
tile or continuously (P = 0.95, P = 0.71, and P = 0.41,
respectively).
Model discrimination
Adding continuous dense breast volume to a model with
BCSC risk model factors showed improved discrimin-
ation of case status (C-statistic 0.627, 95% CI 0.611–
0.642, vs. C-statistic 0.614, 95% CI 0.598–0.630, respect-
ively; P = 0.02) (Table 4). Adding continuous dense
breast volume to a model with BCSC risk model factors
and BMI further increased discriminatory accuracy com-
pared with a model with only BCSC risk model factors
(C-statistic 0.639, 95% CI 0.623–0.654, vs. C-statistic
0.614, 95% CI 0.598–0.630, respectively; P < 0.001). Add-
ing quartiles of dense breast volume to a model with
BCSC risk model factors and BMI had less discrimin-
ation than a model with continuous dense breast volume
(C-statistic 0.629, 95% CI 0.614–0.645) (model results
not shown).
Absolute breast cancer risk combining BI-RADS density
and dense breast volume
The mean 5-year breast cancer risk for women with BI-
RADS heterogeneously or extremely dense breasts is
2.0%. The 5-year risk is higher when considering BI-
RADS density and dense breast volume (Table 5). For
example, women with BI-RADS heterogeneously or ex-
tremely dense breasts and fourth-quartile dense breast
volume had a 5-year risk of 2.5%. Overall, the proportion
of women with heterogeneously or extremely dense
breasts with 5-year risk ≥ 2.5% increased from 20.3% to
30.5% when combined with a dense breast volume meas-
ure. The proportion of cancers with heterogeneously
dense breasts and 5-year risk of ≥ 2.5% increased from
24.3% to 37.9% when taking into account a continuous
dense breast volume measure, whereas control subjects
increased from 19.2% to 29.8%, for a net gain of 3.2% of
high-risk women identified as having cancer. For women
with extremely dense breasts, the proportion of breast
cancers increased from 29.2% to 43.1% when taking into
account a continuous dense breast volume measure, and
Table 2 Frequency distribution of volumetric density within Breast Imaging Reporting and Data System breast density categories
Dense breast
volume,b ml
Control subjects Cases
BI-RADS breast densitya BI-RADS breast densitya
a
n = 731
%
b
n = 1557
%
c
n = 1115
%
d
n = 283
%
a
n = 233
%
b
n = 668
%
c
n = 600
%
d
n = 219
%
Quartile 1: ≤ 35.9 30.5 28.0 15.2 9.9 26.2 24.4 9.7 5.9
Quartile 2: 36.0–50.0 32.1 28.5 19.3 15.2 30.0 27.7 17.3 9.1
Quartile 3: 50.1–70.0 27.5 26.3 26.3 20.8 29.6 26.9 25.7 23.7
Quartile 4: 70.1+ 9.8 17.2 39.3 54.1 14.2 21.0 47.3 61.2
BI-RADS Breast Imaging Reporting and Data System
aBI-RADS breast density: a = almost entirely fat, b = scattered fibroglandular densities, c = heterogeneously dense, d = extremely dense
bMeasured with Volpara software
Table 3 Breast cancer risk associated with Breast Imaging Reporting and Data System breast density cross-classified with dense
breast volume
Dense breast
volume,b ml
BI-RADS breast density aa BI-RADS breast density ba BI-RADS breast density ca BI-RADS breast density da Overall
OR (95% CI)c OR (95% CI)c OR (95% CI)c OR (95% CI)c OR (95% CI)c
Quartile 1: ≤ 35.9 0.63 (0.45–0.89) 0.94 (0.72–1.21) 1.03 (0.71–1.49) 1.53 (0.75–3.09) 0.85 (0.71–1.03)
Quartile 2: 36.0–50.0 0.60 (0.43–0.84) 1.00 (reference) 1.25 (0.92–1.69) 1.50 (0.82–2.73) 1.00 (reference)
Quartile 3: 50.1–70.0 0.70 (0.49–0.99) 0.98 (0.76–1.27) 1.43 (1.09–1.89) 2.87 (1.84–4.47) 1.19 (1.00–1.42)
Quartile 4: 70.1+ 0.87 (0.54–1.41) 1.15 (0.87–1.53) 1.67 (1.31–2.12) 2.56 (1.87–3.52) 1.62 (1.36–1.92)
BI-RADS Breast Imaging Reporting and Data System
aBI-RADS breast density: a = almost entirely fat, b = scattered fibroglandular densities, c = heterogeneously dense, d = extremely dense
bMeasured with Volpara software
cAdjusted for age, body mass index, family history of breast cancer, history of breast biopsy, and race/ethnicity. Statistically significant results are shown in
boldface type
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that of control subjects increased from 24.8% to 34.0%, for
a net gain of 4.7% of high-risk women identified as having
cancer. Dense breast volume did not change the predicted
risk significantly for women with BI-RADS almost entirely
fat or scattered fibroglandular breast density.
Discussion
We found that adding a continuous measure of dense
breast volume to risk prediction models which include
BI-RADS breast density and clinical risk factors im-
proves discriminatory accuracy, in particular for women
with heterogeneously or extremely dense breasts.
Among women aged 40–74 years, an estimated 43.3% of
women have dense breasts [16], but not all women with
dense breasts are at increased risk of breast cancer [9].
Adding a volumetric breast density measure may im-
prove discrimination of women with dense breasts who
are considering supplemental screening or primary
prevention, given the wide variation in BI-RADS density
assessment across radiologists [17].
There are no evidence-based consensus guidelines for
screening women with dense breasts. A 2013 Cochrane
review and the evidence review for the 2015 U.S Prevent-
ive Services Task Force recommendations concluded that
no data currently exist to provide evidence for or against
the use of supplemental screening ultrasonography in
Table 4 Multivariable models with Breast Imaging Reporting and Data System breast density, dense breast volume, or both, with
and without adjustment for body mass index
BI-RADS
breast density
Continuous dense
breast volume
BI-RADS breast density
+ continuous dense
breast volume
BI-RADS
breast density
adjusted for BMI
Continuous dense
breast volume adjusted
for BMI
BI-RADS breast density
+ continuous dense
breast volume adjusted
for BMI
ORa
(95% CI)
ORa
(95% CI)
ORa
(95% CI)
ORb
(95% CI)
ORb
(95% CI)
ORb
(95% CI)
BI-RADS breast density
Almost entirely
fat = a
0.74 (0.62–0.89) 0.77 (0.64–0.92) 0.65 (0.54–0.78) 0.69 (0.57–0.84)
Scattered
fibroglandular
densities = b
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Heterogeneously
dense = c
1.34 (1.16–1.55) 1.17 (1.01–1.36) 1.45 (1.25–1.68) 1.26 (1.07–1.48)
Extremely
dense = d
2.01 (1.61–2.51) 1.63 (1.30–2.05) 2.45 (1.93–3.09) 1.93 (1.50–2.48)
Dense breast
volume, ml,
per SDc
1.34 (1.26–1.42) 1.26 (1.18–1.35) 1.33 (1.25–1.42) 1.20 (1.11–1.29)
C-statisticd 0.614 (0.598–0.630) 0.623 (0.607–0.639) 0.627 (0.611–0.642) 0.634 (0.618–0.649) 0.630 (0.614–0.645) 0.639 (0.623–0.654)
BI-RADS Breast Imaging Reporting and Data System, BMI Body mass index
aAdjusted for age, race/ethnicity, history of breast biopsy, family history of breast cancer. Statistically significant results are shown in boldface type
bAdjusted for age, race/ethnicity, history of breast biopsy, family history of breast cancer, BMI. Statistically significant results are shown in boldface type
cMeasured with Volpara software, log-transformed
dC-statistic represents the AUROC
Table 5 Breast Cancer Surveillance Consortium 5-year breast cancer risk by Breast Imaging Reporting and Data System breast density
with the addition of dense breast volume
BI-RADS breast density aa BI-RADS breast density ba BI-RADS breast density ca BI-RADS breast density da
5-year risk, mean (SD) 5-year risk, mean (SD) 5-year risk, mean (SD) 5-year risk, mean (SD)
Dense breast volume,b ml
Quartile 1: ≤ 35.9 0.9 (0.5) 1.6 (0.9) 1.8 (1.1) 1.5 (0.8)
Quartile 2: 36.0–50.0 1.1 (0.6) 1.7 (0.9) 2.1 (1.3) 2.3 (1.7)
Quartile 3: 50.1–70.0 1.0 (0.7) 1.8 (1.1) 2.2 (1.3) 2.4 (1.6)
Quartile 4: 70.1+ 1.2 (0.7) 1.9 (1.2) 2.5 (1.5) 2.5 (1.6)
Mean BCSC 5-year risk 1.0 (0.6) 1.7 (1.0) 2.0 (1.2) 2.0 (1.4)
BCSC Breast Cancer Surveillance Consortium, BI-RADS Breast Imaging Reporting and Data System
aBI-RADS breast density: a = almost entirely fat, b = scattered fibroglandular densities, c = heterogeneously dense, d = extremely dense
bMeasured with Volpara software
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women with dense breasts, and they challenged investiga-
tors to provide such evidence [18, 19]. The 2010 guide-
lines of the Society of Breast Imaging and the American
College of Radiology recommend that ultrasound be con-
sidered as supplemental screening for women at high risk
and in women with dense breasts [20]. Fifty percent of
women with dense breasts have low breast cancer risk
(<1.67% 5-year risk) [9]. Thus, combinations of breast
cancer risk factors and qualitative and quantitative mea-
sures of breast density could be used to better identify
women with dense breasts at high breast cancer risk who
may benefit from a more intense screening strategy.
The variability in the patterns and amounts of dense
tissue portrayed on the mammogram has been charac-
terized by qualitative measures. The Wolfe scale qualita-
tively assesses breast density by classifying images into
one of four patterns (N1 [fatty], P1, P2 [areas of increas-
ing ductal prominence], and DY [significant densities or
dysplasia]) on the basis of quantity and distribution of
breast density [21]. The BI-RADS density qualitative as-
sessment is similar to the Wolfe scale in that it incorpo-
rates the quantity, distribution, and texture of breast
density. New automated commercial technologies are
available to quantify breast density volume using
methods such as VolparaTM and QuantraTM. Texture
features or parenchymal complexity has been evaluated
on film-screen mammography examinations and shown
to be independent of percentage breast density and rela-
tive amounts of fibroglandular tissue [22, 23]. Winkel et
al. [22] showed that the discriminatory accuracy was
highest when a combination of three methods of asses-
sing relative amounts of density and texture on film-
screen mammography examinations were combined.
Automated evaluation of textural features or parenchy-
mal complexity of breast density is under investigation
for digital images, with researchers in several studies
reporting features as independent predictors of breast
cancer risk [24–26]. Our results extend the literature by
showing that an automated quantitative breast density
measure (dense breast volume) available in clinical practice
combined with a qualitative measure that incorporates the
quantity, distribution, and texture of breast density (BI-
RADS breast density) improves the classification of women
with dense breasts at high breast cancer risk.
Among women with dense breasts, 24% are at high
risk of an interval cancer (>1 per 1000 screening exami-
nations) and warrant discussions of supplemental im-
aging [9]. Interval cancer rates are highest among
women with extremely or heterogeneously dense breasts
and BCSC 5-year breast cancer risk of 2.5% or higher
(21% of women with dense breasts) [9]. If continuous
dense breast volume was assessed in combination with
BCSC risk, 30.5% of women with dense breasts would
have a 5-year risk of 2.5% or higher and qualify for
discussions of supplemental imaging or hormone ther-
apy for primary prevention [27]. Moreover, continuous
dense breast volume assessed in combination with BCSC
model risk factors increases the identification of women
with dense breasts at high breast cancer risk to a greater ex-
tent than measuring single-nucleotide polymorphisms [28].
Future studies should confirm whether interval cancer rates
are higher among women with BI-RADS dense breasts and
high dense breast volume than BI-RADS density alone.
This is the largest study to date involving an examin-
ation of the combination of an automated quantitative
measure of dense breast volume and BI-RADS breast
density on digital mammography examinations and their
independent contribution to breast cancer risk. We ex-
amined Volpara’s automated dense breast volume meas-
ure. Other commercially (QuantraTM) and publicly
(LIBRA) [29] available automated breast density software
could be tested to verify our results. We used clinical
BI-RADS density assessments when the definitions from
the BI-RADS fourth edition were available in clinical
practice. Studies using data collected since the release of
the BI-RADS fifth edition, whose categories attempt to
put more emphasis on the masking effect of dense tis-
sue, should be assessed to ensure our results are robust.
In studies for interrater and intrarater reliability of the
BI-RADS categories, investigators have reported moder-
ate to substantial agreement [30–32]. Thus, misclassifi-
cation of BI-RADS categories may have influenced our
results, such that some of the differences we observed
could result in an under- or overestimation of associa-
tions [33]. Our population was predominantly white and
Asian; studies should be repeated with black and His-
panic women to ensure generalizability of results across
all racial/ethnic groups. Last, our study included women
undergoing digital mammography, which is the primary
modality used in the United States. Breast tomosynthesis is
an emerging breast imaging modality that is being used for
breast screening in 40% of certified U.S. facilities as of
August 1, 2017 [34]; as such, the independent contribution
of qualitative and quantitative density measures to breast
cancer risk for this modality needs to be established.
Conclusions
We found that the combination of automated quantita-
tive and qualitative clinical assessments of breast density
can better identify women with dense breasts at high
breast cancer risk than either measure alone. In future
studies, researchers should assess automated dense
breast volume measures in combination with automated
parenchymal complexity features, as well as qualitative
breast density measures, because both may measure
different aspects of breast density than quantitative mea-
sures when assessing breast cancer risk and screening
outcomes [35].
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